The identification of antigens associated with immune-mediated tumor destruction contributes to an improved understanding of the mechanisms underlying protective tumor immunity. Towards this end, we performed a detailed analysis of the targets of high titer antibodies during graft-versusleukemia reactions in patients with advanced myelodysplasia or acute myeloid leukemia who received an autologous, granulocyte-macrophage colony stimulating factor secreting tumor cell vaccine early after allogeneic hematopoietic stem cell transplantation. Our work revealed the evolution of a potent humoral reaction that unexpectedly included antibodies against multiple angiogenic cytokines. The antibodies were detectable early after immunotherapy and manifested a diversification of reactivity over time in patients who achieved prolonged survival. These results highlight a key role for antibodies during graft-versus-leukemia reactions and raise the possibility that angiogenic cytokines might be effectively targeted with immunotherapy.
Statement of translational relevance
The identification of antigens associated with immune-mediated tumor destruction contributes to an improved understanding of the mechanisms underlying protective tumor immunity. Towards this end, we performed a detailed analysis of the targets of high titer antibodies during graft-versusleukemia reactions in patients with advanced myelodysplasia or acute myeloid leukemia who received an autologous, granulocyte-macrophage colony stimulating factor secreting tumor cell vaccine early after allogeneic hematopoietic stem cell transplantation. Our work revealed the evolution of a potent humoral reaction that unexpectedly included antibodies against multiple angiogenic cytokines. The antibodies were detectable early after immunotherapy and manifested a diversification of reactivity over time in patients who achieved prolonged survival. These results highlight a key role for antibodies during graft-versus-leukemia reactions and raise the possibility that angiogenic cytokines might be effectively targeted with immunotherapy.
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Author Manuscript Published OnlineFirst on December 23, 2014; DOI: 10.1158/1078-0432.CCR- Introduction Allogeneic HSCT is curative treatment for some patients with advanced MDS or AML (1) . Disease control with reduced intensity conditioning (RIC) is accomplished principally through a donor-initiated GVL reaction that involves the coordinated interplay of innate and adaptive immune components. Donor T cells detect complexes of host major histocompatibility (MHC) molecules and peptides derived from either leukemia-associated gene products or normal cellular proteins, some of which are polymorphic between donor and host (2) .
Upon stimulation, the transferred lymphocytes orchestrate an anti-leukemic response that includes both direct cytotoxicity and the triggering of additional cellular and humoral effector pathways (3) . The dual recognition of leukemic cells and healthy tissues underlies the close relationship between the therapeutic benefits of GVL and the inflammatory pathology of GVHD (4).
The mechanisms responsible for disease resistance and relapse after allogeneic HSCT remain to be clarified fully, but may involve, at least in some cases, a failure of anti-tumor immunity (3) . In this context, recent clinical investigations in the autologous, non-transplant setting have established the ability of active immunotherapy to potentiate endogenous host responses (5) , raising the possibility that GVL reactions might be similarly intensified. The period early after allogeneic HSCT may be particularly favorable for active immunotherapy (6) . Conditioning regimens compromise mucosal barriers, permitting the release of endogenous microbiota that may activate and mature dendritic cells systemically through engagement of Toll-like and Nod-like receptors (7) . Drug-induced lymphopenia also increases the levels of proinflammatory cytokines such as IL-7, IL-12, and IL-15 that accelerate the reconstitution of effector T cells relative to FoxP3 + regulatory T cells (Tregs) (8) (9) (10) , which promotes immune-mediated tumor destruction.
Research. Based upon promising experiments with tumor cell vaccines in murine bone marrow transplant models (11), we undertook a Phase I trial of immunization with irradiated, autologous myeloblasts engineered by adenoviral mediated gene transfer to secrete GM-CSF early after RIC allogeneic HSCT in patients with high risk MDS and refractory AML (12) . Eligible patients with relapsed or refractory disease underwent allogeneic HSCT from matched donors using fludarabine and busulfan as the conditioning regimen and tacrolimus and pulse methotrexate as GVHD prophylaxis. Between thirty and forty five days after HSCT, fifteen patients began vaccination with autologous gene-modified cells at a median dose of 1.0 x 10 7 cells per injection and a mean GM-CSF secretion rate of 52 ng/10 6 cells/24 hours. Vaccines were administered subcutaneously and intra-dermally at weekly intervals times three and then every other week times three.
Vaccination was well tolerated and did not lead to an exacerbation in frequency or intensity of acute or chronic GVHD. Notwithstanding the concurrent administration of tacrolimus as GVHD prophylaxis, immunization stimulated local infiltrates composed of dendritic cells, granulocytes, macrophages, eosinophils, and lymphocytes. These responses led, likely through priming in regional lymph nodes, to enhanced systemic immunity that was manifested in T cell infiltration into the leukemic bone marrow and T cell mediated delayed-type hypersensitivity reactions to intradermal injections of irradiated, autologous AML cells. Treatment also triggered reductions in the levels of soluble NKG2D ligands, with a corresponding normalization of NKG2D expression on NK cells and CD8 + T lymphocytes. Collectively, these results indicate that vaccination early after allogeneic HSCT augments both innate and adaptive immunity in some patients, thereby intensifying GVL. Moreover, nine of 10 patients who completed the course of six inoculations achieved durable complete remissions.
In the autologous setting, vaccination with irradiated, autologous GM- (13) . Through the screening of tumor-derived cDNA expression libraries with post-vaccination sera, we identified several targets of therapyinduced antibodies, which include intracellular, surface membrane, and secreted proteins (14) (15) (16) (17) (18) (19) . Functional studies revealed that antibodies directed towards surface and secreted proteins could promote tumor cytotoxicity and block key pathways of tumor progression, underscoring an important contribution of humoral immunity to the therapeutic effects. To determine whether the leukemia cell vaccines early after allogeneic HSCT might similarly elicit a coordinated T and B cell reaction that participates in the GVL reaction, we undertook a detailed characterization of antibody responses in the immunized AML/MDS patients.
Research. 
Materials and Methods

Clinical protocol
The Phase I trial of vaccination with lethally irradiated, autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CSF in high risk MDS/AML patients receiving a RIC allogeneic HSCT was reported (12) 
cDNA expression library screening
The construction of the K008 melanoma-derived cDNA expression library was reported (14) . Post-vaccination sera from three patients (9, 12, and 23) were precleared against Escherichia coli and lambda phage lysates and used at a 1:1,000 dilution in TBST (50 mM Tris/138 mM NaCl/2.7 mM KCl/0.05% Tween 20, pH 
Protein microarray screening
The Invitrogen ProtoArray v5.0 (Cat# PAH052501) that contains approximately 9000 human proteins (expressed as glutathione S-transferase fusion proteins in SF9 insect cells) spotted in duplicate on nitrocellulose-coated glass slides (http://orf.invitrogen.com) was used for screening patient sera (1:500 dilution).
After adding an anti- arrays were scanned with a GenePix 4000B Fluorescent Scanner and the data processed using ProtoArray Prospector 2.0 (Invitrogen, Carlsbad, California, USA). Values for each protein were calculated with the Z-factor, which measures the signal to noise ratio.
ELISAs
ELISA plates (Nunc) were coated with 50 μl/well of human proteins in TBS-T (0.1% Tween) overnight at 4 o C. The concentrations were: 3 μg/ml for L1CAM (Sino Biological), 1.5 μg/ml for DEL-1 (R&D), 2 μg/ml for angiopoietin-1 (R&D), 0.5 μg/ml for angiopoietin-2 (R&D), 1 μg/ml for vascular endothelial growth factor-A (Peprotech), 3 μg/ml for progranulin (R&D), 0.4 μg/ml for platelet derived growth factor-BB (eBioscience), and 1 μg/ml for hepatocyte growth factor (Sino Biological). Plates were washed and blocked for 1. 
Statistical analysis
The relationship between survival and antibody response in the first sample post-HSCT was determined with a Cox proportional hazards model. 
Results
Screening for antibody targets
To explore the development of humoral immunity during GVL reactions associated with vaccination early after allogeneic HSCT, we first sought to define specific gene products that were the targets of high titer antibodies. Postvaccination sera from three patients who achieved long-term disease control were employed to screen a previously constructed melanoma-derived cDNA expression library (K008) that has proved informative for antigen discovery efforts in several other tumor types (14) (15) (16) (17) (18) (19) . While the use of the K008 library limits the ability to detect leukemia-specific antigens, it favors the identification of shared tumor antigens that may include proteins commonly involved in transformation. The three screens yielded a total of ninety-nine clones that encoded thirty-six distinct gene products, thirty-four of which are known proteins ( Table 1) Table 1 Author Manuscript Published OnlineFirst on December 23, 2014; DOI: 10.1158/1078-0432.CCR- activities. From this perspective, developmental endothelial locus-1 (Del-1) and tyrosine kinase with immunoglobulin and epidermal growth factor homology domains 2 (Tie-2) emerged of interest. Del-1 is a secreted protein composed of a phosphatidylserine binding domain and an epidermal growth factor (EGF) domain that contains a canonical arginine-glycine-aspartate (RGD) motif (27) .
Through engagement with the cognate α v β 3 and α v β 5 integrins expressed on endothelial cells, Del-1 mediates potent angiogenic activity (28) . Tie-2 is a receptor tyrosine kinase expressed on endothelial cells that cooperates with vascular endothelial growth factor receptor signaling to promote blood vessel formation (29) . Overall, the two screening approaches raised the possibility that vaccination stimulated antibodies against angiogenic factors.
Validating angiogenic cytokines as antibody targets
To confirm the results of the screening studies and to develop a system more amenable to analysis of a larger number of patient samples, we established (Table 2) .
Given the induction of antibodies to five functionally related proteins, we expanded the analysis to include additional proteins involved in angiogenesis.
These included: vascular endothelial growth factor A (VEGF-A) and macrophage migration inhibitory factor (MIF), which we earlier described as antibody targets (19) ; progranulin (31) and platelet derived growth factor-BB (PDGF-BB) (32), which we identified through other screening studies using sera from melanoma patients; and hepatocyte growth factor (HGF), which was recently implicated in leukemogenesis (33) . Among these candidates, post-vaccination sera from Patient 12 recognized VEGF-A (Table 2 ). To determine whether other vaccinated AML/MDS patients developed antibodies to the panel of angiogenic cytokines, we examined sera obtained approximately one month after the last vaccination in the entire cohort of fifteen patients (Table 2) . No reactivity to MIF was detected in any patient; the basis for this difference compared to solid tumors remains to be clarified. However, nine patients showed responses to at least one of the antigens, and five patients harbored antibodies to five or more factors.
Longitudinal analysis of antibody development
To learn more about the kinetics of antibody development, we performed a time-course analysis for each antigen in all of the immunized patients.
Examples of reactivity to individual angiogenic cytokines are presented in Figure   1 . Considerable heterogeneity was evident in the patterns of responses. For example, Patient 9 rapidly generated antibodies to angiopoietin-1 and PDGF-BB upon vaccination, whereas these were sustained for several years. In contrast, To quantify the magnitude of increase in antibody response, we compared serial dilutions of the samples with highest reactivity for each antigen with baseline levels in the pre-vaccination sera. Representative studies that illustrate differing levels of antibody induction are shown in Figure 2 . In Patient 11, the peak antibodies to PDGF-BB display a modest elevation relative to pre-vaccine levels (two to three fold), whereas the antibodies to HGF manifest a greater augmentation (six fold). An even larger increase in antibodies to angiopoietin-1
Research. (ten fold) was evident for Patient 27. Based on these examples, we classified treatment response as "+" for two and one-half to five fold increases, "++" for five to seven fold increases, and "+++" for eight and greater fold increases. Table   2 summarizes the results of the semi-quantitative analysis for all antigens and patients. Patients that mounted antibody responses to multiple angiogenic cytokines also generated the strongest increases in antibody titers, often against several targets. In contrast, patients that generated antibodies to only a few or one of the antigens showed only modest increases in antibody titers. Together, these results reveal heterogeneity in the breadth and intensity of response to angiogenic cytokines.
Clinical associations of early antibody responses
To understand the potential clinical associations of the humoral reactions, we assessed the development of antibodies to individual antigens as a function of clinical course. For this analysis, we considered the time to antibody response as the first sera sample after the initiation of vaccination in which antibody titers had increased at least two and one-half fold above pre-treatment levels.
Although this time-point may not reflect the peak titer, we were interested in determining the point at which immune responsiveness first became evident. Figure 3A displays the longitudinal courses for the fifteen vaccinated patients. Of the six patients who succumbed to disease within the first two years after HSCT, only three mounted antibodies to at least one antigen, and these were only of modest intensity (Table 2) . In contrast, all six of the patients who developed antibodies to multiple cytokines, which were often of high intensity, achieved prolonged survival. Nonetheless, not all of the long-term survivors showed reactivity to these gene products, suggesting that additional important targets may remain to be discovered. For those patients who developed multiple antibodies, a diversification of reactivity was evident over time, but generally occurred within two years of HSCT and vaccination. However, two patients Because the early development of antibodies appeared to be linked with a subsequent diversification of reactivity, we wondered whether the initial antibody response might also be associated with clinical outcome. To address this issue, we analyzed the presence of antibodies in the first post-vaccination sample available, which ranged from 1.1 to 3.9 months after allogeneic-HSCT.
The median follow-up time among survivors in the study is currently 69 months (range 62 to 85). As shown in Figure 3B , patients with antibodies to two or more angiogenic cytokines at an early time point showed improved survival compared to subjects with zero or one antibody. Although the magnitude of the difference appears substantive, it does not reach statistical significance due to the limited size of the patient cohort (5-year overall survival: 67% vs. 33%, respectively, p=0.13). This potential association will be tested more rigorously through a recently initiated randomized trial comparing vaccination to placebo in a larger but similar patient population. and CD8 + T cell responses. Additionally, antibodies directed against tumor cell surface or secreted proteins may promote Fc receptor dependent cytotoxicity or blockade of major oncogenic functions respectively.
The selection of a melanoma cDNA expression library and protein microarray for antigen discovery biased our search towards gene products that might be shared among tumor types. The utility of this strategy was suggested through our earlier report that one of the AML patients immunized early after allogeneic HSCT generated antibodies to protein disulfide isomerase, a vaccine target originally uncovered in a renal cell carcinoma system (36) . In accordance with this finding, the screening efforts with the AML/MDS sera yielded a large number of proteins involved in fundamental aspects of cell biology. Most targets were intracellular in location, but L1CAM, Del-1, and Tie-2 were of particular interest due to their surface expression/secretion profiles and functional interrelatedness.
Angiogenesis is considered a hallmark of cancer in solid malignancies (37), but its role in leukemogenesis is less well established (38) . Histopathologic examination of AML and MDS patient bone marrows reveals increased microvessel density (39, 40) while non-invasive imaging suggests that the degree of vascularity might have prognostic importance (41) . Furthermore, the circulating levels of several angiogenic factors are frequently elevated in leukemic patients (38) . A cross-talk of bone marrow endothelial cells and stem cells is increasingly being recognized to regulate normal and malignant hematopoiesis (42) . In this regard, endothelial cells promote the survival of leukemic progenitors through contact dependent and soluble factors, whereas leukemic cells provide angiogenic proteins that support endothelial cell growth/remodeling and new blood vessel formation (43) . 
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Although responses to Tie-2 could not be analyzed in detail, the cognate ligands angiopoietin-1 and angiopoietin-2 evoked reactivity in some patients, consistent with their immunogenicity in vaccinated solid tumor patients (19) . Underscoring the common targeting of angiogenesis with GM-CSF secreting vaccines, we also detected antibodies to VEGF-A, progranulin, and PDGF-BB, which had been identified through other screens performed in immunized melanoma patients.
Moreover, HGF, an angiogenic growth factor that also contributes to AML through cell autonomous effects on leukemic blasts (33), proved to be another antibody target. The induction of humoral reactions to as many as seven angiogenic cytokines in long-term responding AML/MDS patients emphasizes the potential importance of this oncogenic pathway for GVL responses. Indeed, it is tempting to speculate that high levels of angiogenic proteins, which may derive from either autologous myeloblasts or bone marrow stromal elements retained within the vaccine inoculum, might be rendered immunogenic through GM-CSF stimulated dendritic cell antigen presentation combined with alloreactivity. While the long-term responding patients also generated anti-leukemic T cells, as evidenced in delayed-type hypersensitivity reactions to irradiated, autologous leukemia cells and T cell infiltrates in bone marrow (12) , further studies are required to determine whether these T cells recognize peptides derived from the angiogenic cytokines. Examples of reactivity to PDGF, hepatocyte growth factor, and angiopoietin-1 are presented for patients 11 and 27. See Table 2 
